We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer is expanding further into oncology thanks to a deal with Myovant Sciences, under which the two companies will cooperate on developing and commercializing Myovant’s newly approved prostate cancer drug Orgovyx (relugolix). Myovant will receive up to $4.2 billion, including an upfront payment of $650 million. Read More
The president’s controversial “most favored nation” strategy for lowering U.S. drug prices has been placed on hold by a federal judge pending an evaluation of its legality. Read More
President Trump signed Congress’ combined appropriations and COVID-19 relief package late on Sunday, averting a looming federal government shutdown. Read More
The FDA rapped California-based drug manufacturer Sky Systems in a Form 483 with a dozen observations after an inspection revealed the firm lacked a quality control unit. Read More
By the end of 2022, drug, device and biologic product sponsors that are required to submit a risk evaluation and mitigation strategy (REMS) will have to do so electronically, the FDA said in a final guidance issued last week. Read More
In 2020, messenger RNA (mRNA), the technology behind Pfizer’s and Moderna’s COVID-19 vaccine, practically became a household word. Now the gate is open for more mRNA vaccines to flood the space. Read More
Swedish drugmaker Vicore Pharma has reported positive results from a phase 2 study evaluating its oral therapy for treating respiratory infection in hospitalized COVID-19 patients. Read More
Merck has signed a contract to supply up to 100,000 doses of its experimental COVID-19 treatment, MK-7110, to the U.S. government for $356 million, provided the investigational biologic earns the FDA’s approval or Emergency Use Authorization. Read More